BCL-2 Family Proteins as Therapeutic Targets in Multiple Myeloma - Episode 6

Venetoclax in Combination with Daratumumab for Multiple Myeloma Treatment

,

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. A look at clinical trial efficacy data on daratumumab plus bortezomib and venetoclax for multiple myeloma treatment.

EP. 1: An Overview of Multiple Myeloma
EP. 2: The Role of BCL-2 in Normal and Multiple Myeloma Cells
EP. 3: Venetoclax Monotherapy for the Treatment of Multiple Myeloma
EP. 4: Venetoclax plus Dexamethasone for Multiple Myeloma Treatment
EP. 5: Venetoclax for Multiple Myeloma: The Phase 3 BELLINI Trial
Now Viewing
EP. 6: Venetoclax in Combination with Daratumumab for Multiple Myeloma Treatment
EP. 7: Venetoclax in Combination with Carfilzomib for Multiple Myeloma Treatment
EP. 8: Other Venetoclax-based Combination Regimens Being Evaluated in Multiple Myeloma
EP. 9: Other Investigational Agents Targeting BCL-2 Family Proteins for Multiple Myeloma Treatment
EP. 10: Where Does Inhibition of BCL-2 Family Proteins Fit into the Multiple Myeloma Treatment Landscape?